|
Study of Anti-Inflammatory Effects of Dapagliflozin As Add on Treatment Versus Metformin with Placebo Among Diabetic Patients in Thi-Qar City, South of Iraq
|
|
| Author:
|
, METHAQ A.M.HUSSEIN, LAYTH JABBAR
|
| Abstract:
|
Background: Dapagliflozin is a drug that belong to medications group named sodium glucose cotransporter2 (SGLT) inhibitor it was used for its action as anti-hyperglycemic effect through its action on the
cotransporter which is located in proximal tubule of the nephron and by this action will facilitate the urine
excretion of glucose and weight loss.1
Aim: Aim of this current study is to investigate the anti-inflammatory effects of Dapagliflozin among type II
diabetic patients when added to their basic treatment in Thi-Qar city, South of Iraq.
Method: 63 Diabetic patients was divided into 2 groups (Group A 32 patients who received Metformin plus
placebo, Group B 31 patients who received Metformin plus Dapagliflozin) were checked for the inflammatory
mediator levels including Hs-CRP through their visits to private clinics or Al-Hussain teaching hospital in ThiQar in during 2020.
Results: After serial follow up with patients for 9 months through measuring their Hs-CRP for period of 9
months the findings were there is significant differences between the two groups as there is significant
decrease in the level of Hs-CRP of group B versus group A.
Conclusion: We find out, Dapagliflozin when used for 9 months in patients with diabetes mellitus who was
used metformin and when Dapagliflozin was added to their treatment the reduction in the level of Hs-CRP
was significantly decreased after the monitoring during the 9 months’ period through measuring its level every
3 months.
|
| Keyword:
|
Dapagliflozin, Metformin, Hs- CRP, Diabetes mellitus, inflammatory mediator.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP2.572
|
| Download:
|
Request For Article
|
|
|